A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT05121103 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic business decision

Conditions

Multiple Myeloma, Refractory
Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma Refractory
Multiple Myeloma in Relapse

Interventions

DRUG: EZM0414

Sponsor

Epizyme, Inc.